Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • M.D., University of Michigan, Ann Arbor 2013
• 

  Previous Appointments & Affiliations

  • Assistant Professor of Dermatology, Dermatology, Clinical Science Departments 2017 - 2020
• 

  Leadership & Clinical Positions at Duke

  • Managing Director - Dermatology Clinical Research Unit
    
    Medical Director - Teledermatology Service
    
    
    
• Research
• 

  Selected Grants

  • To assess the safety and tolerability of single agent RP1 in selected organ transplant recipients awarded by Replimune Group, INC 2021 - 2025
  • A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients with Recurrent Cutaneous Squamous Cell Carcinoma (CSCC) awarded by Regeneron Pharmaceuticals, Inc. 2019 - 2024
  • A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell C awarded by PellePharm 2019 - 2023
  • A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, STRATIFIED, VEHICLE-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF SIROLIMUS 3.9% TOPICAL GEL IN PREVENTION OF BCCS IN PATIENTS WITH GORLIN SYNDROME awarded by Palvella Therapeutics, Inc 2021 - 2023
  • Pelle-926-301E: A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects with Gorlin Syndrome (Basal Cell Nevus Syndrome) awarded by PellePharm 2020 - 2023
  • A Multicenter, Randomized, Double blind, Vehicle-controlled, Phase 2 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell C awarded by PellePharm 2020 - 2023
  • Qualification of the Methodology to Identify and Measure Basal Cell Carcinomas (BCCs) on the face of patients with Basal Cell Nevus Syndrome (Gorlin Syndrome) or Sporadic BCCs awarded by PellePharm 2018 - 2020
• 

  External Relationships

  • LeoPharma
  • Spectrum Pharmaceuticals Inc.
  • Sun Pharmaceuticals
  • Teladoc
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Leckey, Bruce D., Meenal K. Kheterpal, M Angelica Selim, and Rami N. Al-Rohil. “Cutaneous involvement by T-cell prolymphocytic leukemia presenting as livedoid vasculopathy.” J Cutan Pathol 48, no. 7 (July 2021): 975–79. https://doi.org/10.1111/cup.14023.
       Full Text  Link to Item
    • Xia, Meng, Meenal K. Kheterpal, Samantha C. Wong, Christine Park, William Ratliff, Lawrence Carin, and Ricardo Henao. “Malignancy Prediction and Lesion Identification from Clinical Dermatological Images.” Corr abs/2104.02652 (2021).
       Open Access Copy
    • Patel, A. D., S. Ravichandran, and M. Kheterpal. “Hedgehog inhibitors with and without adjunctive therapy in treatment of locally advanced basal cell carcinoma.” International Journal of Dermatology, January 1, 2021. https://doi.org/10.1111/ijd.15836.
       Full Text
    • Ravichandran, Surya, and Meenal K. Kheterpal. “Apremilast for the off-label treatment of lichenoid and interface dermatoses.” J Am Acad Dermatol 83, no. 5 (November 2020): 1489–91. https://doi.org/10.1016/j.jaad.2020.05.112.
       Full Text  Link to Item
    • Kheterpal, Meenal K., Julia Dai, Shamir Geller, Melissa Pulitzer, Andy Ni, Patricia L. Myskowski, Alison Moskowitz, et al. “Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin.” J Am Acad Dermatol 81, no. 4 (October 2019): 970–76. https://doi.org/10.1016/j.jaad.2019.01.037.
       Full Text  Link to Item
    • Kelsey, Chris R., Endi Wang, Alexandra Stefanovic, and Meenal Kheterpal. “Radiation therapy for primary cutaneous γδ T-cell lymphoma: Case report and literature review.” Jaad Case Rep 5, no. 7 (July 2019): 582–86. https://doi.org/10.1016/j.jdcr.2019.05.002.
       Full Text  Open Access Copy  Link to Item
    • Fixsen, Emma, Jigar Patel, Maria Angelica Selim, and Meenal Kheterpal. “Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine.” Oncologist 24, no. 3 (March 2019): e103–5. https://doi.org/10.1634/theoncologist.2018-0531.
       Full Text  Link to Item
    • Lebowitz, E., S. Geller, E. Flores, M. Pulitzer, S. Horwitz, A. Moskowitz, M. Kheterpal, and P. L. Myskowski. “Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients.” Journal of the European Academy of Dermatology and Venereology 33, no. 1 (January 2019): 108–14. https://doi.org/10.1111/jdv.15236.
       Full Text
    • Pulitzer, Melissa, Shamir Geller, Erica Kumar, Denise Frosina, Alison Moskowitz, Steven Horwitz, Patricia Myskowski, et al. “T-cell receptor-δ expression and γδ+ T-cell infiltrates in primary cutaneous γδ T-cell lymphoma and other cutaneous T-cell lymphoproliferative disorders.” Histopathology 73, no. 4 (October 2018): 653–62. https://doi.org/10.1111/his.13671.
       Full Text
    • Geller, Shamir, Haoming Xu, Mark Lebwohl, Beatrice Nardone, Mario E. Lacouture, and Meenal Kheterpal. “Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.” American Journal of Clinical Dermatology 19, no. 3 (June 2018): 363–75. https://doi.org/10.1007/s40257-017-0337-2.
       Full Text
    • Warren, Shay, Meenal Kheterpal, Patricia L. Myskowski, Alison Moskowitz, Steven M. Horwitz, and Melissa P. Pulitzer. “Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control study.” Journal of the American Academy of Dermatology 78, no. 3 (March 2018): 530–39. https://doi.org/10.1016/j.jaad.2017.09.015.
       Full Text
    • Quaglino, P., M. Maule, H. M. Prince, P. Porcu, S. Horwitz, M. Duvic, R. Talpur, et al. “Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.” Annals of Oncology 28, no. 10 (October 2017): 2517–25. https://doi.org/10.1093/annonc/mdx352.
       Full Text
    • Georgesen, Corey, Meenal Kheterpal, and Melissa Pulitzer. “A Rare Case of Cutaneous Plasmacytosis in a Korean Male.” Case Reports in Pathology 2017 (2017): 1–6. https://doi.org/10.1155/2017/3032941.
       Full Text
    • Kheterpal, Meenal, Neha Mehta-Shah, Pooja Virmani, Patricia L. Myskowski, Alison Moskowitz, and Steven M. Horwitz. “Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides.” Current Hematologic Malignancy Reports 11, no. 3 (June 2016): 224–33. https://doi.org/10.1007/s11899-016-0322-5.
       Full Text
    • Nghiem, B. T., M. Kheterpal, M. Dandekar, M. Chan, L. Lowe, and F. Wang. “Adult-onset eccrine angiomatous hamartoma: report of a rare entity with unusual histological features.” Journal of the European Academy of Dermatology and Venereology 28, no. 7 (July 2014): 981–83. https://doi.org/10.1111/jdv.12335.
       Full Text
    • Kheterpal, Meenal K., and Charles N. Ellis. “The impact of dermatology in premier medicine journals.” Skinmed 9, no. 5 (September 2011): 288–92.
       Link to Item
    • Gunawardena, Shanaka R., Brian L. Ruis, Julia A. Meyer, Meenal Kapoor, and Kathleen F. Conklin. “NOM1 Targets Protein Phosphatase I to the Nucleolus.” Journal of Biological Chemistry 283, no. 1 (January 2008): 398–404. https://doi.org/10.1074/jbc.m706708200.
       Full Text
    • Simmons, Heidi M., Brian L. Ruis, Meenal Kapoor, Andrew W. Hudacek, and Kathleen F. Conklin. “Identification of NOM1, a nucleolar, eIF4A binding protein encoded within the chromosome 7q36 breakpoint region targeted in cases of pediatric acute myeloid leukemia.” Gene 347, no. 1 (February 2005): 137–45. https://doi.org/10.1016/j.gene.2004.12.027.
       Full Text
    • Kheterpal, Meenal, and Shamir Geller. “Low-Grade Cutaneous B-cell Lymphoma in African American Patients geller,” n.d.

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.